WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2010/023482    International Application No.:    PCT/GB2009/051084
Publication Date: 04.03.2010 International Filing Date: 28.08.2009
C07K 16/28 (2006.01), A61K 39/395 (2006.01), A61P 37/06 (2006.01)
Applicants: ISIS INNOVATION LTD [GB/GB]; Ewert House Ewert Place, Summertown Oxford Oxfordshire OX2 7SG (GB) (For All Designated States Except US).
COBBOLD, Stephen [GB/GB]; (GB) (For US Only).
DALEY, Stephen, Robert [AU/AU]; (AU) (For US Only).
FREWIN, Mark, Raymond [GB/AU]; (AU) (For US Only).
WALDMANN, Herman [GB/GB]; (GB) (For US Only)
Inventors: COBBOLD, Stephen; (GB).
DALEY, Stephen, Robert; (AU).
FREWIN, Mark, Raymond; (AU).
WALDMANN, Herman; (GB)
Agent: ELKINGTON AND FIFE LLP; Prospect House 8 Pembroke Road Sevenoaks Kent TN13 1XR (GB)
Priority Data:
0815788.5 29.08.2008 GB
Abstract: front page image
(EN)A process for inducing tolerance to an antigen in a patient comprising administering to said patient an effective amount of an anti-CD40L antibody over a period of up to 4 weeks without subsequent re-administration after this period for at least 6 months, wherein the antibody consists of Fab or F(ab')2 fragments or contains mutations in the Fc region which prevent binding of the antibody to Fc receptors. Chimeric anti-CD40L antibodies and uses thereof.
(FR)L'invention concerne un procédé d'induction d'une tolérance à un antigène chez un patient, qui comprend l'administration audit patient d'une quantité efficace d'un anticorps anti-CD40L sur une période pouvant atteindre 4 semaines sans ré-administration ultérieure après cette période pendant au moins 6 mois. Selon l'invention, l'anticorps est constitué de fragments Fab ou F(ab')2 ou contient des mutations dans la région Fc qui empêchent la liaison de l'anticorps aux récepteurs Fc. L'invention concerne également des anticorps anti-CD40L chimériques et leurs utilisations.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)